摘要
Hepatocellular carcinoma(HCC)is one of the most common cancers worldwide.According to the Barcelona Clinic Liver Cancer(BCLC)staging system,transarterial chemoembolization(TACE)is the first-line recommendation for intermediate-stage HCC.In real-world clinical practice,TACE also plays an important role in early-and advanced-stage HCC.This review article by the experts from Chinese Liver Cancer Clinical Study Alliance(CHANCE)summarizes the available clinical evidence pertaining to the current application of TACE in patients with early-,intermediate-,and advanced-stage HCC.In addition,combination of TACE with other treatment modalities,especially immunotherapy,is reviewed.
基金
supported by the National Natural Science Foundation of China (81901847)
the Natural Science Foundation of Jiangsu Province (BK20190177)。